Category: Hot Mandates

Hot Life Science Investor Mandate 1: Single Family Office Seeking Global Opportunities in Brain Health

~ Next Phase Admin ~ Leave a comment

A Single Family Office based in the western United States makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million.  The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania.

The firm focuses on brain health, with 80% of the fund’s investments occurring in this indication area.  The firm’s mandate encompasses both diseases of the nervous system and psychiatric disorders, with a particular interest in Alzheimer’s disease.  The firm is open to investing in therapeutics, diagnostics and medical devices, and is interested in interdisciplinary approaches.  The firm seeks early-stage opportunities, but will also consider later-stage opportunities.  The firm’s prior investments include drug discovery for treatments for Alzheimer’s disease, and novel diagnostics including a tool that tracks early cognitive decline.

The firm strongly prefers to invest in privately held companies.  The firm only backs top scientists pursuing breakthrough approaches, and does not invest in “me-too” ideas.  In the medical technology sector the firm prefers to invest in companies developing platform technologies with multiple potential applications.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Health Insurance Provider Seeking Shipping Medical Devices/Diagnostics

~ Next Phase Admin ~ Leave a comment

A US based Health Insurance Provider makes investments in healthcare companies from an evergreen investment fund.  Allocation sizes are highly varied, but are most often $3-5 million.  While the firm is open to opportunities globally, the organization only invests in companies that are targeting the US healthcare market (including companies with products that have been commercialized in other markets and are seeking capital to expand into the US market).

The firm invests in transformative medical technologies that will lower the cost of care provision, and has previously made investments in healthcare IT and in wearable sensors for elderly patients.  The firm only invests in companies that have attained regulatory approval for their products, or which do not require approval.  The fund does not invest in therapeutics, but is open to investing in diagnostic technologies that will lower the cost of care.  In the medical device sector, the firm is generally not interested in invasive devices such as implantable.

While the firm is open to investing in any indication area, the firm’s focus is on population health and the firm is therefore primarily interested in indications with a large number of patients, including cancer, diseases of the nervous system, and diabetes.

The firm invests in both pre-revenue companies and companies with existing revenues, but does not invest in companies that still face regulatory barriers to attaining revenue.  The firm has long-term horizons for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: VC Fund Looking Opportunistically in the Life Sciences

~ Next Phase Admin ~ Leave a comment

A Venture Capital company with offices in the Eastern and Western United States is looking to make equity investments ranging from approximately $3-$5 million initially and $10-$25 million over the investment’s lifetime. The firm looks for companies primarily in the United States, and some select opportunities in Europe. The firm plans to make between 1-5 investments over the next year.

The firm is interested in sectors of Biotech Therapeutics, Diagnostics, Medical Devices, Life Science Tools and Healthcare IT. In the Therapeutics space the firm is looking for both small molecule and biologics that are 1 year from entering clinical trials or later with a preference for companies that have in human data. The firm is generally open to all indications but is especially interested in areas of Oncology, Immunology and Orphan Diseases. For Medical Devices, Diagnostics and Life Science Tools the firm prefers to make later stage investments into companies that have significant in human data or have already been commercialized.

The firm is looking for experienced management teams and generally requires a board seat. The firm looks to take company through significant value inflection points acting as a very hand on investor. The firm almost always leads or co-leads investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 1: Singapore VC Fund Looking to Help Companies Expand to Asia

~ Next Phase Admin ~ Leave a comment

A venture capital firm based in Singapore is looking to make early, growth, expansion, and mezzanine stage investments in the healthcare sector. The firm typically invests in the Series A and B rounds. The firm has raised two funds to date. The firm seeks to invest in non-Asian companies that are interested in entering the Asian market; investment funds are prioritized to companies looking to set up operations in Singapore. The firm will also invest in companies based in Asia. The investment size is variable depending on the stage of the company; ranging from $1M to $10M or more. The firm will consider opportunities from around the globe and is actively seeking new investment opportunities. 

The firm seeks to invest in biopharmaceuticals, diagnostics, and medical devices. For therapeutics, the firm prefers novel small molecules and biologics targeting indications in large markets. The firm prefers to invest in platform technologies and typically invests in clinical stage opportunities. For medical devices, the firm prefers devices in the later stages of development or near commercialization. The firm seeks a strong management team and considers both private and public companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Australian VC Looking Overseas for Life Science Opportunities

~ Next Phase Admin ~ Leave a comment

A venture capital firm headquartered in Melbourne, Australia is looking to make makes equity investments from $3M-5M. The firm anticipates about 6 new investments this year and looks to invest invests globally.

The firm will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. The firm considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. The firm seeks investments in novel technology and is not looking to gain share of an existing market.

The firm is open to co-investments and considers public or private companies. The group will only consider companies with granted patents or a clear patent strategy. Companies of interest must have a remote connection with Australia or the Pacific Region. This may include a facility or a partner located in the region.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: Single Family Office Looking to Catalyze Larger Funding Rounds

~ Next Phase Admin ~ Leave a comment

A Family Office based in the Eastern United States is looking to make equity investments into early stage companies in the life science space that can be used to catalyze larger rounds from other institutional investors. The firm’s typical allocation size is between $200,000-$500,000. The firm is currently looking for companies around the US. The firm is looking to make approximately 4 investments over the next 6-9 months.

The firm is currently looking for companies developing therapeutics and is open to both small molecules and biologics. The firm is generally open to all indications within these areas including orphan indications. The firm is willing to invest in both pre-clinical and clinical stage companies with a preference for those with some in-human data.

The firm is looking for privately held companies with experienced management teams. The firm’s main mission is to help companies catalyze larger rounds by helping attract other more large scale investors. The firm looks to take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 1: Global Pharmaceutical Company Seeking Therapeutic In-Licensing/Investment Opportunities

~ Next Phase Admin ~ Leave a comment

A global biopharmaceutical company with offices in the US and Europe is looking to in-license technology of interest and also makes select equity investments. The investment size is highly variable and has ranged from $1 million to $10s of millions. The firm invests in companies so the candidate technology can improve the lives of patients, not to make financial returns. The group does not have a goal for the number of deals this year. The firm made over 10 deals in the past year, and a few of these were equity investments. The group considers partnerships and investments globally.

The firm is interested in therapeutic biotechnology. The group is platform agnostic and will consider small molecules, biologics, or cell and gene therapy. Primary indications of interest include oncology, hematology, inflammation, and immunology. The firm will consider orphan indications but is less interested in ultra-orphan indications. The firm will consider companies across all phases of development, with a slight preference for later stage companies.

The firm prefers companies with experienced management teams and often seeks a board observer seat. Technologies of interest are generally not yet profitable. For equity deals, the firm does not want to be the first investor and prefers opportunities that have previous VC involvement. The group prefers to syndicate with other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com